StemCell Therapy

Pancreatic cancer is a deadly malignancy with few treatment models. Monolayer cell culture has failed to predict patient drug responses in the past. In response to this, a patient-derived organoid (PDO) methodology has been developed that enables the generation of models, from both surgically resected material and biopsies, with a success rate of 75-80%. These cultures enable the molecular dissection of treatment responses and resistance.

Here, Dannielle Engle and Christian Oberdanner will discuss the use of the Tecan SparkCyto to evaluate drug responses in PDO models. In short, PDO models were plated in a 384-well format, allowed to reform, and treated with compounds. The dose-responses of PDO models were compared to several agents using both CellTiter-Glo (Promega) to measure ATP levels, as well as the automated confluence measurement. This methodology provided the same endpoint analyses previously relied upon, plus the dynamic evaluation of changes to cell morphology and confluence. Confluence measurements were found to be comparable to ATP levels. Given the diversity observed amongst pancreatic cancer patients and the PDO models, dynamic measurements provide additional flexibility and information for precision medicine approaches.

Key learning objectives:

Who should attend:

Read the original:
Predicting drug responses using pancreatic cancer organoids and multimodal plate imaging on SelectScience - SelectScience

This entry was posted on May 27, 2020 at 11:47 am and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |